<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00664417</url>
  </required_header>
  <id_info>
    <org_study_id>FUF04</org_study_id>
    <nct_id>NCT00664417</nct_id>
  </id_info>
  <brief_title>Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine</brief_title>
  <official_title>Safety and Immunogenicity of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following the licensure of sanofi pasteur's 90 µg rgA/Vietnam/1203/2004 pandemic influenza
      vaccine, efforts to develop a lower antigen dose formulation with improved immunogenicity
      using adjuvants were initiated. The present study is part of this endeavor. It is primarily a
      formulation/dose-finding study with a secondary aim at generating safety and immunogenicity
      data for the final formulation for the development of a pre-pandemic vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, observer-blinded, randomized, controlled multicenter, dose-finding study
      in adult subjects. All vaccines will be administered as a two-dose schedule in (H5N1)
      immunologically-naïve adults. Immunogenicity and safety will be evaluated after each
      injection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the safety after primary administration of A/H1N1 vaccine</measure>
    <time_frame>6 months post-vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">375</enrollment>
  <condition>Influenza</condition>
  <condition>Orthomyxoviridae Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent subvirion H5N1 influenza vaccine</intervention_name>
    <description>0.5 mL, IM, 2 injections, Formulation 1</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent subvirion H5N1 influenza vaccine</intervention_name>
    <description>0.5 mL, IM, 2 injections, Formulation 2</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent subvirion H5N1 influenza vaccine</intervention_name>
    <description>0.5 mL, IM, 2 injections, Formulation 3</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent subvirion H5N1 influenza vaccine</intervention_name>
    <description>0.5 mL, IM, 2 injections, Formulation 4</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent subvirion H5N1 influenza vaccine</intervention_name>
    <description>0.5 mL, IM, 2 injections, Formulation 5</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent subvirion H5N1 influenza vaccine</intervention_name>
    <description>0.5 mL, IM, 2 injections, Formulation 6</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent subvirion H5N1 influenza vaccine</intervention_name>
    <description>0.5 mL, IM, 2 injections, Comparator 1</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent subvirion H5N1 influenza vaccine</intervention_name>
    <description>0.5 mL, IM, 2 injections, Comparator 2</description>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Physiological saline</intervention_name>
    <description>0.5 mL, IM, 2 injections</description>
    <arm_group_label>9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Healthy adult aged 18 to 40 years on the day of inclusion.

          -  Provides signed informed consent prior to study procedures.

          -  Able to attend all scheduled visits and comply with all trial procedures.

          -  For a woman of child-bearing potential, avoid becoming pregnant (use of an effective
             method of contraception or abstinence) for at least 4 weeks prior to the first
             vaccination, until at least 4 weeks after last vaccination.

        Exclusion Criteria :

          -  Known systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to the standard-dose Fluzone® vaccine or to a vaccine
             containing any of the same substances

          -  For a woman of child-bearing potential, known pregnancy or positive serum/urine
             pregnancy test

          -  Breast feeding woman

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the 4 weeks preceding the (first) trial vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,
             oral, parenteral, or inhaled steroids

          -  Has an acute or chronic medical illness or any condition that would, in the opinion of
             the site investigator, place the subject at an unacceptable risk of injury or would
             interfere with the evaluation of responses or render the subject unable to meet the
             requirements of the protocol

          -  Known or suspected current alcohol abuse or drug addiction that may interfere with the
             subject's ability to comply with trial procedures

          -  History of receipt of blood or immunoglobulin or other blood-derived products within
             the 3 months prior to enrollment in this study that might interfere with the
             assessment of immune response

          -  Receipt of any vaccine in the 4 weeks preceding the first trial vaccination

          -  Planned receipt of any vaccine in the 4 weeks preceding or following any trial
             vaccination

          -  Known Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen, or Hepatitis C
             seropositivity

          -  Personal or family history of Guillain-Barré Syndrome

          -  Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding
             inclusion contraindicating IM vaccination

          -  Active neoplastic disease or a history of any hematologic malignancy

          -  Previous participation in a pandemic flu trial

          -  History of H5N1 infection or exposure to presumed/confirmed H5N1 human/animal cases

          -  Known seizure/epilepsy history and/or taking anti-seizure medication

          -  Receipt of psychiatric drugs. Subjects receiving a single antidepressant drug and
             stable for at least 3 months prior to enrollment, without decompensating symptoms will
             be allowed to enroll in the study.

          -  Subject deprived of freedom by an administrative or court order, or in an emergency
             setting, or hospitalized without his/her consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2008</study_first_posted>
  <last_update_submitted>April 16, 2012</last_update_submitted>
  <last_update_submitted_qc>April 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>A/H5N1</keyword>
  <keyword>Orthomyxoviridae Infections</keyword>
  <keyword>Influenza Pandemics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
    <mesh_term>Orthomyxoviridae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

